Johnna E Perdrizet (Johnna Perdrizet)

Publication Activity (10 Years)

Years Active: 2021-2024
Publications (10 Years): 31

Top Topics

Tyrosine Kinase

Top Venues

Infectious diseases and therapy

Human vaccines & immunotherapeutics

Expert review of vaccines

Expert review of pharmacoeconomics & outcomes research

This page only lists publications with an associated author ORCID identifier.

Publications

An Ta, Felicitas Kühne, Maren Laurenz, Christof von Eiff, Sophie Warren, Johnna E Perdrizet
Cost-effectiveness of PCV20 to Prevent Pneumococcal Disease in the Pediatric Population: A German Societal Perspective Analysis. Infectious diseases and therapy 13 (6) (2024)
An Ta, Felicitas Kühne, Maren Laurenz, Christof von Eiff, Sophie Warren, Johnna E Perdrizet
Cost-effectiveness of PCV20 to Prevent Pneumococcal Disease in the Pediatric Population: A German Societal Perspective Analysis. Infectious diseases and therapy 13 (6) (2024)
An Ta, Felicitas Kühne, Maren Laurenz, Christof von Eiff, Sophie Warren, Johnna E Perdrizet
Cost-effectiveness of PCV20 to Prevent Pneumococcal Disease in the Pediatric Population: A German Societal Perspective Analysis. Infectious diseases and therapy (2024)
Johnna E Perdrizet, Mark H Rozenbaum, Matthew J Heffler
Pediatric Pneumococcal Conjugate Vaccine and Dosing Schedule Perceptions Among Health Care Providers and Caregivers in Germany, France, Spain, and Greece. Infectious diseases and therapy (2024)
Ann-Charlotte Fridh, Andreas Palmborg, An Ta, Donata Freigofaite, Sophie Warren, Johnna E Perdrizet
An economic evaluation of pneumococcal conjugate vaccines, PCV20 versus PCV15, for the prevention of pneumococcal disease in the Swedish pediatric population. Human vaccines & immunotherapeutics 20 (1) (2024)
Masayoshi Shinjoh, Kanae Togo, Tomoyuki Hayamizu, Naohiro Yonemoto, Junko Morii, Johnna E Perdrizet, Kazumasa Kamei
Cost-effectiveness analysis of 20-valent pneumococcal conjugate vaccine for routine pediatric vaccination programs in Japan. Expert review of vaccines 23 (1) (2024)
Masayoshi Shinjoh, Kanae Togo, Tomoyuki Hayamizu, Naohiro Yonemoto, Junko Morii, Johnna E Perdrizet, Kazumasa Kamei
Cost-effectiveness analysis of 20-valent pneumococcal conjugate vaccine for routine pediatric vaccination programs in Japan. Expert review of vaccines (2024)
Johnna E Perdrizet, Mark H Rozenbaum, Matthew J Heffler
Pediatric Pneumococcal Conjugate Vaccine and Dosing Schedule Perceptions Among Health Care Providers and Caregivers in Germany, France, Spain, and Greece. Infectious diseases and therapy (2024)
Masayoshi Shinjoh, Kanae Togo, Tomoyuki Hayamizu, Naohiro Yonemoto, Junko Morii, Johnna E Perdrizet, Kazumasa Kamei
Cost-effectiveness analysis of 20-valent pneumococcal conjugate vaccine for routine pediatric vaccination programs in Japan. Expert review of vaccines 23 (1) (2024)
Johnna E Perdrizet, Mark H Rozenbaum, Matthew J Heffler
Pediatric Pneumococcal Conjugate Vaccine and Dosing Schedule Perceptions Among Health Care Providers and Caregivers in Germany, France, Spain, and Greece. Infectious diseases and therapy 13 (9) (2024)
Johnna E Perdrizet, Mark H Rozenbaum, Matthew J Heffler
Pediatric Pneumococcal Conjugate Vaccine and Dosing Schedule Perceptions Among Health Care Providers and Caregivers in Germany, France, Spain, and Greece. Infectious diseases and therapy 13 (9) (2024)
Johnna E Perdrizet, Mark H Rozenbaum, Matthew J Heffler
Pediatric Pneumococcal Conjugate Vaccine and Dosing Schedule Perceptions Among Health Care Providers and Caregivers in Germany, France, Spain, and Greece. Infectious diseases and therapy 13 (9) (2024)
An Ta, Felicitas Kühne, Maren Laurenz, Christof von Eiff, Sophie Warren, Johnna E Perdrizet
Cost-effectiveness of PCV20 to Prevent Pneumococcal Disease in the Pediatric Population: A German Societal Perspective Analysis. Infectious diseases and therapy 13 (6) (2024)
Chanthawat Patikorn, Warittakorn Kategeaw, Johnna E Perdrizet, Xiuyan Li, Nathorn Chaiyakunapruk
Implementation challenges and real-world impacts of switching pediatric vaccines: A global systematic literature review. Human vaccines & immunotherapeutics 19 (1) (2023)
Chanthawat Patikorn, Warittakorn Kategeaw, Johnna E Perdrizet, Xiuyan Li, Nathorn Chaiyakunapruk
Implementation challenges and real-world impacts of switching pediatric vaccines: A global systematic literature review. Human vaccines & immunotherapeutics 19 (1) (2023)
Chanthawat Patikorn, Warittakorn Kategeaw, Johnna E Perdrizet, Xiuyan Li, Nathorn Chaiyakunapruk
Implementation challenges and real-world impacts of switching pediatric vaccines: A global systematic literature review. Human vaccines & immunotherapeutics (2023)
Michele Wilson, Cheryl McDade, Anna Trisia Beby-Heijtel, Angela Waterval-Overbeek, Vishalini Sundaram, Johnna E Perdrizet
Assessing Public Health Impact of Four Pediatric Pneumococcal Conjugate Vaccination Strategies in the Netherlands. Infectious diseases and therapy (2023)
Chanthawat Patikorn, Warittakorn Kategeaw, Johnna E Perdrizet, Xiuyan Li, Nathorn Chaiyakunapruk
Implementation challenges and real-world impacts of switching pediatric vaccines: A global systematic literature review. Human vaccines & immunotherapeutics 19 (1) (2023)
Xiuyan Li, Sophie Warren, Mark H Rozenbaum, Johnna E Perdrizet
Reanalysis of the Clinical and Economic Burden of Pneumococcal Disease Due to Serotypes Contained in Current and Investigational Pneumococcal Conjugate Vaccines in Children < 5 Age: A Societal Perspective. Infectious diseases and therapy 12 (3) (2023)
Chanthawat Patikorn, Warittakorn Kategeaw, Johnna E Perdrizet, Xiuyan Li, Nathorn Chaiyakunapruk
Implementation challenges and real-world impacts of switching pediatric vaccines: A global systematic literature review. Human vaccines & immunotherapeutics 19 (1) (2023)
Xiuyan Li, Sophie Warren, Mark H Rozenbaum, Johnna E Perdrizet
Reanalysis of the Clinical and Economic Burden of Pneumococcal Disease Due to Serotypes Contained in Current and Investigational Pneumococcal Conjugate Vaccines in Children < 5 Age: A Societal Perspective. Infectious diseases and therapy 12 (3) (2023)
Xiuyan Li, Sophie Warren, Mark H Rozenbaum, Johnna E Perdrizet
Reanalysis of the Clinical and Economic Burden of Pneumococcal Disease Due to Serotypes Contained in Current and Investigational Pneumococcal Conjugate Vaccines in Children < 5 Age: A Societal Perspective. Infectious diseases and therapy (2023)
Johnna E Perdrizet, Emily K Horn, Kyla Hayford, Lindsay Grant, Rachid Barry, Liping Huang, Cheryl McDade, Michele Wilson
Historical Population-Level Impact of Infant 13-Valent Pneumococcal Conjugate Vaccine (PCV13) National Immunization Programs on Invasive Pneumococcal Disease in Australia, Canada, England and Wales, Israel, and the United States. Infectious diseases and therapy (2023)
Johnna E Perdrizet, Emily K Horn, Winniefer Nua, Judith Perez-Peralta, Jennifer M Nailes, Jaime Santos, Anna Ong-Lim
Response to Gomez et al.'s Letter to the Editor Regarding: "Cost-Effectiveness of the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) Versus Lower-Valent Alternatives in Filipino Infants". Infectious diseases and therapy 11 (4) (2022)
Johnna E Perdrizet, Emily K Horn, Winniefer Nua, Judith Perez-Peralta, Jennifer M Nailes, Jaime Santos, Anna Ong-Lim
A Response to: Letter to the Editor Regarding "Cost-Effectiveness of the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) Versus Lower-Valent Alternatives in Filipino Infants". Infectious diseases and therapy 11 (3) (2022)
Johnna E Perdrizet, Raymond A Farkouh, Emily K Horn, Kyla Hayford, Heather L Sings, Matthew Wasserman
The broader impacts of otitis media and sequelae for informing economic evaluations of pneumococcal conjugate vaccines. Expert review of vaccines 21 (4) (2022)
Juan Manuel Reyes-Sanchez, Jorge LaRotta, Gamboa N Castaño, Mark A Fletcher, Matthew Wasserman, Johnna E Perdrizet, Rodrigo Sini de Almeida
Letter to the editor regarding "Budget impact analysis of pneumococcal conjugate vaccines in Colombia". Expert review of pharmacoeconomics & outcomes research (2021)
Canna Jagdish Ghia, Emily K Horn, Gautam Rambhad, Johnna E Perdrizet, Ramaa Chitale, Matthew Wasserman
Estimating the Public Health and Economic Impact of Introducing the 13-Valent Pneumococcal Conjugate Vaccine or 10-Valent Pneumococcal Conjugate Vaccines into State Immunization Programs in India. Infectious diseases and therapy 10 (4) (2021)
Johnna E Perdrizet, Emily K Horn, Winniefer Nua, Judith Perez-Peralta, Jennifer M Nailes, Jaime Santos, Anna Ong-Lim
Cost-Effectiveness of the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) Versus Lower-Valent Alternatives in Filipino Infants. Infectious diseases and therapy 10 (4) (2021)
Matthew Wasserman, Johnna E Perdrizet, Lindsay Grant, Kyla Hayford, Shubhra Singh, Paranjoy Saharia, Emily K Horn, Raymond A Farkouh
Clinical and Economic Burden of Pneumococcal Disease Due to Serotypes Contained in Current and Investigational Pneumococcal Conjugate Vaccines in Children Under Five Years of Age. Infectious diseases and therapy 10 (4) (2021)
Johnna E Perdrizet, Yuen S Lai, Scott Williams, Valda A Struwig, Matt Wasserman
Retrospective Impact Analysis and Cost-Effectiveness of the Pneumococcal Conjugate Vaccine Infant Program in Australia. Infectious diseases and therapy 10 (1) (2021)